Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

297
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
297
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

191
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
191
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

110
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
110
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

56
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
56
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

74
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
74
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

114
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
114

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrence outcome and prediction model of patients with gastric cancer underwent laparoscopic-assisted total gastrectomy: A retrospective study.

Surgery·2026
Same author

Preoperative PNI-dNLR Score as Predicting Long-Term Survival in Older Adults Undergoing Radical Gastrectomy for Gastric Cancer.

Clinical interventions in aging·2026
Same author

Can combined biochemical and radiological responses enhance prognostic assessment after neoadjuvant therapy for locally advanced gastric cancer? A multicenter real-world study.

Surgical endoscopy·2026
Same author

Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study.

World journal of surgical oncology·2026
Same author

Post-surgical lymph node status guides perioperative chemotherapy completion for locally advanced gastric cancer.

Surgical endoscopy·2026
Same author

CT assessment of body composition and liver fat fraction predicts prognosis in gastric cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Related Experiment Video

Updated: May 22, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

199

Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after

Qi-Chen He1,2,3,4, Ze-Ning Huang1,2,3,4, Chen-Bin Lv5

  • 1Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, Fuzhou, 350001, Fujian Province, China.

BMC Cancer
|March 14, 2025
PubMed
Summary

Helicobacter pylori (HP) infection is associated with improved survival in advanced gastric cancer (AGC) patients undergoing neoadjuvant chemotherapy (NAC). Combining NAC with adjuvant chemotherapy (AC) further enhances outcomes for HP-positive AGC patients.

Keywords:
Helicobacter pyloriGastrectomyGastric cancerNeoadjuvant chemotherapy

More Related Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

948
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

240

Related Experiment Videos

Last Updated: May 22, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

199
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

948
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

240

Area of Science:

  • Oncology
  • Gastroenterology
  • Infectious Diseases

Background:

  • Neoadjuvant chemotherapy (NAC) improves outcomes for advanced gastric cancer (AGC).
  • The impact of Helicobacter pylori (HP) infection on survival after NAC for AGC remains unstudied.

Purpose of the Study:

  • To investigate the effect of HP infection on the postoperative survival of AGC patients treated with NAC.

Main Methods:

  • Retrospective cohort study of 307 AGC patients undergoing laparoscopic gastrectomy post-NAC.
  • Survival analysis using Kaplan-Meier and Cox regression to identify prognostic factors.

Main Results:

  • HP-positive patients showed significantly better 3-year overall survival (OS) and disease-free survival (DFS) than HP-negative patients (OS: 75.9% vs. 60.2%; DFS: 70.2% vs. 52.3%).
  • For HP-positive patients, ypTNM Stage III, NAC ≥4 cycles, and adjuvant chemotherapy (AC) ≥4 cycles were independent prognostic factors for OS.
  • HP-positive patients receiving ≥4 cycles of NAC and ≥4 cycles of AC had superior 3-year OS (92.5%) compared to those receiving <4 cycles of AC (71.4%).

Conclusions:

  • HP infection is linked to a better prognosis in AGC patients following NAC.
  • For potentially resectable HP-positive AGC, radical surgery combined with ≥4 cycles of NAC and ≥4 cycles of sequential AC is recommended to improve survival.